Nakamichi S, Kubota K, Misumi T, Kondo T, et al. Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non-small-cell lung cancer: TORG1937 (DATE study). Clin Cancer Res 2024 Jan 2. doi: 10.1158/1078-0432.CCR-23-2568.
PMID: 38165684